Debbie Allen has been active in the antibody engineering field since the 1980s. She brings to argenx more than 30 years of corporate and business development experience with small and large biotech companies focused on biopharmaceuticals. Dr. Allen is an inventor of HUMIRA® (adalimumab). She established her business development career at Cambridge Antibody Technology (acquired by Astra Zeneca), where she had management responsibility for technology, intellectual property and product out-licensing, corporate equity, co-development and cross-license agreements. She was responsible for the 1999 license agreement with Human Genome Sciences that led to the discovery of the antibody drug BENLYSTA®(belimumab), now approved for the treatment of systemic lupus erythematosus.
Prior to joining argenx, Dr. Allen acted as an independent consultant to around 25 emerging biotech companies, providing strategic management and business development support.